-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lung cancer remains the leading cause of cancer-related deaths worldwide (about 1.
TRC102 is a small molecule base excision repair inhibitor.
This is a phase I clinical trial that evaluated the optimal dose, efficacy and safety of pemetrexed and TRC102 combined with cisplatin radiotherapy in the treatment of stage III non-squamous non-small cell lung cancer (NS-NSCLC)
Progression-free survival
Progression-free survivalFrom 2015 to 2019, a total of 15 patients were recruited
3 patients achieved complete remission (20%), 12 patients achieved partial remission (80%), 3 patients achieved complete remission (20%), and 12 patients achieved partial remission (80%) for 6 months The progression-free survival rate was 80%, and the 2-year overall productivity was 83%
Overall survival rate
Overall survival rateIn summary, the safety and tolerability of pemetrexed combined with TRC102, cisplatin and radiotherapy for non-squamous non-small cell lung cancer are good
The safety and tolerability of pemetrexed combined with TRC102 and cisplatin and radiotherapy for non-squamous cell carcinoma and non-small cell lung cancer are well tolerated Both safety and tolerability are good
Original source:
Original source:Biswas Tithi,Dowlati Afshin,Kunos Charles A et al.
Leave a message here